HIND.US Vyome Holdings, Inc.
- Market cap
- USD 11.1M
- P/E
- 0.9x
- P/B
- 1.84x
- ROE
- -63.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is HIND.US undervalued?
Graham numberThe Graham number of Vyome Holdings, Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vyome Holdings, Inc. fundamental analysis
No fundamental analysis for Vyome Holdings, Inc. yet.
Vyome Holdings, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vyome Holdings, Inc.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908,…
Full company profileVyome Holdings, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Vyome Holdings, Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 787K | 1.29M | 607K | 15.1M | 11.3M | 13.6M | 11.2M | 8.68M | 8.01M | 320K | 155K |
| Gross Profit | 355K | 351K | 442K | 9.31M | 6.26M | 8.35M | 6.80M | 5.55M | 5.06M | 207K | 70.0K |
| Operating Income | -22.8M | -31.4M | -38.5M | -24.5M | -12.5M | -57.9M | -27.1M | -14.6M | -7.73M | -2.75M | -4.02M |
| EBITDA | -19.9M | -32.5M | -36.7M | -72.9M | -18.1M | -60.6M | -44.3M | -11.2M | -6.65M | -10.3M | -3.49M |
| Net Income | -23.4M | -33.8M | -81.2M | -74.2M | -21.6M | -63.1M | -46.2M | -11.4M | -7.13M | -10.3M | -3.38M |
| EPS | - | -4,397,656 | -9,274,466 | -3,373,045 | -503,023 | -418,185 | -157,727 | -2,773 | -346 | -4.75 | -0.48 |
| Balance Sheet | |||||||||||
| Total Assets | 7.04M | 88.7M | 46.3M | 39.7M | 39.7M | 52.5M | 11.3M | 10.7M | 4.79M | 6.50M | 8.61M |
| Total Liabilities | 4.10M | 12.3M | 14.6M | 15.5M | 25.2M | 8.20M | 7.60M | 4.06M | 5.05M | 2.74M | 2.07M |
| Shareholders' Equity | 2.94M | 76.4M | 31.7M | 24.1M | 14.5M | 44.3M | 3.66M | 6.66M | -253K | 2.44M | 5.33M |
| Cash & Short-term Investments | 3.31M | 10.2M | 5.55M | 2.94M | 3.01M | 22.8M | 3.96M | 4.56M | 693K | 4.98M | 6.96M |
| Total Debt | 144K | 489K | 6.31M | 5.41M | 13.3M | 279K | 171K | 262K | 967K | 31.3K | 353K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -20.7M | -24.6M | -27.5M | -14.2M | -8.55M | -15.4M | -21.9M | -17.0M | -4.43M | -3.75M | -4.68M |
| Capital Expenditure | 14.0K | 137K | 49.6K | 14.0K | 390K | 352K | 131K | 43.0K | 0.00 | 3.00 | 8.00 |
| Free Cash Flow | -20.7M | -24.7M | -27.5M | -14.2M | -8.94M | -15.7M | -22.0M | -17.0M | -4.43M | -3.75M | -4.68M |
| Ratios | |||||||||||
| ROE | -794.9% | -44.3% | -256.3% | -307.8% | -149.3% | -142.4% | -1,262.3% | -170.9% | - | -420.2% | -63.4% |
| ROA | -331.8% | -38.1% | -175.4% | -187.1% | -54.5% | -120.2% | -410.2% | -106.2% | -148.8% | -157.9% | -39.2% |
| Net Profit Margin | -2,969.6% | -2,627.3% | -13,375.7% | -491.8% | -191.4% | -464.3% | -411.2% | -131.2% | -89.1% | -3,209.7% | -2,174.2% |
| Debt to Equity | 0.05x | 0.01x | 0.20x | 0.22x | 0.91x | 0.01x | 0.05x | 0.04x | - | 0.01x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Vyome Holdings, Inc. dividends
Vyome Holdings, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4 on Aug 15, 2025.
Who owns Vyome Holdings, Inc.
- Insiders 52.89%
- Institutions 2.05%
- Public & others 45.07%
- Shares outstanding 7.02M
- Free float 3.65M
Top funds holding HIND.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 16.2K | 0.23% | 0.00% | Sep 2026 |
| Cinvest Multigestión Garp FI | 5.80K | 0.08% | 0.00% | Sep 2026 |
| Fintech Income SICAV | 5.80K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 3.21K | 0.05% | 0.00% | Sep 2026 |
Top institutions holding HIND.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Citadel Advisors Llc | 26.0K | 0.37% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 25.8K | 0.37% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 20.3K | 0.29% | 0.00% | Jun 2026 |
| The Colony Group LLC | 14.6K | 0.21% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 12.2K | 0.17% | 0.00% | Jun 2026 |
| UBS Group AG | 11.9K | 0.17% | -47.48% | Jun 2026 |
| Susquehanna International Group, LLP | 10.1K | 0.14% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 9.46K | 0.13% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 5.86K | 0.08% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 1.81K | 0.03% | +29.98% | Jun 2026 |
| Barclays PLC | 26.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 3.00 | 0.00% | +50.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
Vyome Holdings, Inc. company profile
- Company name
- Vyome Holdings, Inc.
- Ticker
- HIND.US
- Exchange
- USA Stocks
- Listed since
- Oct 6, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 9
- Fiscal year end
- December
- Address
- Harvard Square, Cambridge, MA, United States, 02138
- Phone
- 973 832 8147
- Website
- vyometx.com
About Vyome Holdings, Inc.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
Vyome Holdings, Inc. management
7- Mr. Venkateswarlu Nelabhotla M.B.A.Co-Founder, CEO, President & Director · born 1962
- Dr. Shiladitya Sengupta M.Sc., Ph.D.Co-Founder, Director and Member of Scientific & Clinical Advisory Board · born 1973
- Mr. Jerry Leonard CPA, M.B.A.CFO, Principal Financial & Accounting Officer · born 1968
- Dr. Richard Fahrner Ph.D.Chief Technology Officer
- Mr. Jules AbrahamInvestor Relations Officer
- Dr. Charles G. Chavdarian Ph.D.Senior Vice President of Product Development & Regulatory CMC
- Dr. Tamara Agajanov M.D.Senior Vice President of Clinical Development